Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Globe Newswire•27/08/2026•15:29 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.